Illustration: Lazaro Gamio/Axios

HOUSTON — Power from offshore wind is finally poised for liftoff in the U.S.

Why it matters: The U.S. has long been a laggard, but that's poised to change thanks to a convergence of forces that analysts see bringing enough coastal wind online over the next decade to power millions of homes.

What's happening: A huge energy conference here in the nation's oil-and-gas capital offers a window into what's prompting giant energy companies to plan multibillion dollar investments. It's a story of...

  • Atlantic Coast states moving ahead with zero-emissions power procurement policies.
  • Oil-and-gas majors expanding their low-carbon power portfolios.
  • Technology evolution and falling costs.
  • The Trump administration supporting the development even as it abandons Obama-era climate programs.

What they're saying: "The missing piece for some time was actually an interest from the states up along the coast to acquire this power from this industry," says Christer af Geijerstam, who heads U.S. wind efforts for the oil-and-gas giant Equinor.

  • "That's where we have seen the significant shift the last 2–3 years being led by New York and Massachusetts," he tells Axios while at the big CERAWeek by IHS Markit conference.

ICYMI: In December, Equinor was among the winning bidders in a federal auction of development sites that are off the Massachusetts coast.

  • This adds to another site in federal waters off New York that it had acquired in 2016.
  • They paid $135 million for the Massachusetts site in the Interior Department auction that brought in a record-shattering $405 million.
  • I asked if Equinor would bid in federal lease auctions in the planning stages off New York and California. He said yes and offered no caveats.

The big picture: IHS Markit's current forecast sees 7 gigawatts of offshore wind coming online in the U.S. by 2030, up from almost nothing today. But that estimate could rise.

  • "We will be looking carefully at what the outcome of solicitations in Massachusetts and New Jersey and New York is going to be," IHS associate director Max Cohen says.
  • Bloomberg NEF already projects 11.4 gigawatts of capacity by 2030. They've upped their estimate thanks to a combination of specific solicitations and long-term targets by state governments in Virginia, New Jersey and elsewhere.

Where it stands: Equinor is among several deep-pocketed companies in the space planning projects. Here are some other players...

  • Danish wind giant Orsted bought the U.S. firm Deepwater Wind last year.
  • A joint venture between Shell and EDP also had a winning bid in the recent Massachusetts sale. "The U.S. has a magnificent wind resource right next to a large population and highly densely populated areas," Enrique Alvarez Uria of EDP Renewables said at a panel here yesterday. He estimated EDP's effort with Shell could be a $4 billion to $6 billion capital investment.
  • Vineyard Wind, which is co-owned by Copenhagen Infrastructure Partners and Iberdrola's Avangrid Renewables, snapped up a lease that adds to their plans for a separate project in the region.

What we're hearing: One real but hard to quantify factor is the role shareholder pressure plays in the moves by oil majors to diversify into renewables.

  • “The changing ESG [environmental, social and governance] landscape is really going to move capital,” Jonathon Kaufman, the co-head of the power and renewables group at Credit Suisse, said at a separate panel discussion yesterday.
  • Kaufman tells me that for oil majors, the growing moves into renewables require a balance between competing goals, particularly when fossil fuel projects deliver higher margins.
  • "There's this tension between putting money into something that's much lower returns, but also evolving their business mix," he adds.

The intrigue: Offshore wind has long been a big thing in Europe. But one irony of the U.S. delay in entering this sector is the upside of being a late mover — lower costs.

  • "The U.S. came late to the show, but they’re certainly sort of reaping the technology benefits from Europe," af Geijerstam said, noting the projects here start "really, really low on the cost trajectory."

Go deeper

13 mins ago - Health

Top business leaders urge White House to develop mandatory mask guidelines

A man walks past a Ramen restaurant in Los Angeles, California on July 1. Photo: Frederic J. Brown/AFP via Getty Images

The heads of the U.S. Chamber of Commerce, Business Roundtable, National Retail Federation and other top business organizations wrote an open letter on Thursday urging the White House coronavirus task force to work with governors to make face coverings mandatory in all public spaces.

Driving the news: An analysis led by Goldman Sachs' chief economist found that a national mandate requiring face coverings would "could potentially substitute for lockdowns that would otherwise subtract nearly 5% from GDP," the Washington Post reports.

Updated 44 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 3:30 p.m. ET: 10,763,604 — Total deaths: 517,667 — Total recoveries — 5,522,094Map.
  2. U.S.: Total confirmed cases as of 3:30 p.m. ET: 2,715,124 — Total deaths: 128,439 — Total recoveries: 729,994 — Total tested: 32,827,359Map.
  3. Public health: What we know about the immune response to coronavirus and what it means for a vaccine.
  4. Politics: Herman Cain hospitalized for COVID-19 after attending Trump Tulsa rally — Biden downplays jobs number, rebukes Trump for ignoring health crisis.
  5. States: Florida reports more than 10,000 new coronavirus cases — 5 states saw 27% spike in heart-related deaths in first 3 months of coronavirus pandemic.

The other immune responders to COVID-19

Illustration: Eniola Odetunde/Axios

Scientists are inching closer to understanding how antibodies and immune cells are unleashed by the body in response to the novel coronavirus.

Why it matters: Natural immunity differs from that afforded by vaccination but it offers clues for the design of effective vaccines and therapies.